.
of the life claims declined, 0.85 per cent were due to mis-representation and 0.16 per cent due to the definition of terminal illness not being met. .
china's plans to import indian drugs fail to enthuse indian pharmaceutical firms
.
.
.
. at this, shehbaz reassured them that the interview was taken out of context. this is unedited, unformatted feed from the press trust of india wire..
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance..
Take up to 10% off with code